Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy (MANTRA)
Efficacy of Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy: Impact on Recovery and Early Hospital Discharge.
研究概览
详细说明
Prospective, randomized, controlled clinical trial to evaluate whether multimodal anesthesia allows for early hospital discharge (reduce 24-hour admission) compared to conventional anesthesia in oncological robotic nephrectomies; both according to usual practice. The effect of no specific drug will be evaluated, but rather the anesthetic approach pologies of surgical patients. It will be enrolled 80 patients. Patients will be randomized 1:1 using a computer-generated sequence into: Group A: multimodal anesthesia vs Group B: conventional anesthesia.
Main objective is to demonstrate the superiority of multimodal anesthesia over conventional anesthesia in patients undergoing robotic laparoscopic nephrectomy within a short-stay surgical program, in terms of reducing hospital admission time and earlier discharge. To demonstrate that multimodal anesthesia allows a reduction in hospital admission time allowing for early discharge.
Estimated duration of the study is 18 months. This involves collecting data from preoperative to 30 days post-surgery from patients undergoing oncological robotic nephrectomy.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:DIANA VERNETTA, MD
- 电话号码:0034934169700
- 邮箱:dvernetta@fundacio-puigvert.es
学习地点
-
-
BARCELONA
-
Barcelona、BARCELONA、西班牙、08025
- 招聘中
- Fundacio Puigvert
-
接触:
- DIANA VERNETTA, MD
- 电话号码:0034934169700
- 邮箱:dvernetta@fundacio-puigvert.es
-
接触:
- Silvia Mateu, MD
- 电话号码:0034 934169700
- 邮箱:smateu@fundacio-puigvert.es
-
首席研究员:
- DIANA VERNETTA, MD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patients ≥18 years.
- Indication for elective oncological robotic partial or radical nephrectomy.
- ASA classification I-III.
- Candidates for short-stay surgery according to institutional protocol.
- Signed informed consent.
Exclusion Criteria:
- Chronic opioid use. Defined as continuous opioid use during the 3 months prior to surgery
- Uncontrolled chronic pain. Defined as chronic pain not adequately controlled with usual treatment during the 3 months prior to surgery.
- Contraindications to NSAIDs, regional anesthesia, or drugs of the multimodal protocol.
- Advanced renal failure (GFR <30 ml/min) at the preanesthetic visit.
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Multimodal anesthesia
Multimodal anesthesia Balanced general anesthesia. Standardized multimodal analgesia: Paracetamol iv NSAID or COX-2 (if not contraindicated) Magnesium sulfate iv Lidocaine iv Ketamine iv Methadone iv at the beginning surgical incision at low doses TAP block with local anesthetic: Bupivacaine 0.25% 10ml Surgical wound infiltration with local anesthetic: bupivacaine 0.25% 2ml per to knock |
Administration of multimodal anesthesia in patients randomized to this arm and undergoing oncological robotic nephrectomies according to usual practice. Premedication: Midazolam: 1-2mg Ondansetron: 4-8mg IV Dexamethasone: 4-8mg IV +/-Scopolamine (patients high risk PONV) iv Magnesi Sulfate: 30-50mg/Kg iv Induction: Fentanyl: 1mcg/kg iv Propofol: 1-2mg/Kg iv Rocuroni: 0.3mg/kg iv Lidocaine: 1.1.5mg/Kg iv bolus Ketamine: 0.25-0.5mg/Kg Methadone: 0.5-0.1mg/kg IV at the beginning of the surgical incision (single dose). Maintenance: Propofol/sevorane Rocuroni: 0.3mg/kg/h iv Lidocaine: 1-2 mg/Kg/h Ketamine: 0.1-0.2 mg/kg/h Postoperative: Paracetamol: 1g/8h IV Metamizole: 1g/8h iv Rescue opioids if VAS>4: Adolonta or Morphine |
|
有源比较器:Conventional anesthesia
Balanced general anesthesia. Standardized conventional analgesia: Paracetamol IV NSAID or COX-2 (if not contraindicated) Analgesia based mainly on systemic opioids. Absence of protocolized regional blocking. |
Administration of conventional anesthesia in patients randomized to this arm and undergoing oncological robotic nephrectomies according to usual practice. Premedication: Midazolam: 1-2mg Ondansetron: 4-8 mg IV Dexamethasone: 4-8 mg IV +/-Scopolamine (patients high risk PONV) iv Induction: Fentanyl: 1mcg/kg iv Propofol: 1-2mg/kg iv Rocuroni: 0.3mg/kg iv Maintenance: Propofol/sevorane Rocuroni: 0.3mg/kg/h iv Remifentanil: 0.05-0.2 mcg/Kg/h Methadone: 1-1.5mg/kg IV at the end of surgery Postoperative: Paracetamol: 1g/8h IV Metamizole: 1g/8h iv Rescue opioids if VAS>4: Adolonta or Morphine. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change hospital admission time and earlier discharge
大体时间:From enrollment to the end of follow up 30 days
|
Changes over time in the hospital stay, expressed in hours, will be measured and reported.
|
From enrollment to the end of follow up 30 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Post surgery pain
大体时间:Post surgery time 6, 24 and 48 hours.
|
Postoperative pain will be assessed using the VAS scale (Visual Analogue Scale) at 6, 24 and 48 hours.
The results will be recorded on a scale of 0 (minimal pain) to 10 (maximum pain).
|
Post surgery time 6, 24 and 48 hours.
|
|
Cumulative consumption of opioids
大体时间:From enrollment to the end of follow up 30 days
|
Compare the cumulative consumption of opioids (morphine equivalents).
|
From enrollment to the end of follow up 30 days
|
|
Nausea and vomiting
大体时间:From enrollment to the end of follow up 30 days
|
Compare the incidence of postoperative nausea and vomiting (PONV).
|
From enrollment to the end of follow up 30 days
|
|
Early ambulation
大体时间:From end of surgery to ambulation
|
Compare the time in hours from end of surgery to early ambulation during hospitalization.
|
From end of surgery to ambulation
|
|
Oral tolerance
大体时间:From end of surgery to oral tolerance
|
Compare the time in hours from end of surgery to oral tolerance during hospitalization.
|
From end of surgery to oral tolerance
|
|
Hospital stay
大体时间:From enrrolment to end of hospital stay
|
Compare the time of hospital stay in hours from hospitalization to discharged.
|
From enrrolment to end of hospital stay
|
|
Duration of surgery
大体时间:From start surgery to end surgery
|
Compare the duration of surgery in hours
|
From start surgery to end surgery
|
|
Perioperative complications
大体时间:From enrollment to the end of follow up 30 days
|
Compare perioperative complications according to the Clavien-Dindo classification.
It grades complications from I (menor) to V (major), with suffix 'd' for permanent disability.
|
From enrollment to the end of follow up 30 days
|
|
Readmission or unscheduled consultations
大体时间:From enrollment to the end of follow up 30 days
|
Compare the rate of readmission or unscheduled consultations at 30 days.
|
From enrollment to the end of follow up 30 days
|
|
Postoperative recovery
大体时间:From enrollment to the end of follow up 30 days
|
Assess the quality of postoperative recovery using the QoR-15 questionnaire (Quality of Recovery-15).
It consists of 15 items that assess pain, physical comfort, physical independence and emotional state, with a total score ranging from 0 to 150 (the higher the score, the better the recovery)
|
From enrollment to the end of follow up 30 days
|
|
Surgical procedure satisfaction
大体时间:From enrollment to the end of follow up 30 days
|
Compare the level of general satisfaction with the surgical procedure using a satisfaction questionnaire based on the Likert scale: Very dissatisfied, Dissatisfied, Neutral, Satisfied, Very satisfied.
|
From enrollment to the end of follow up 30 days
|
|
Predictive factors for better response to multimodal anesthesia
大体时间:From enrollment to the end of follow up 30 days
|
Determine predictive factors for better response to multimodal anesthesia (e. g.: age report in years, sex (male or female), the ASA (American Society of Anesthesiologists) classification (I-VI), weight and height will be combined to report BMI in kg/m^2, pathological history, nephrectomy, bleeding, perioperative complications).
|
From enrollment to the end of follow up 30 days
|
合作者和调查者
调查人员
- 首席研究员:DIANA VERNETTA, MD、FUNDACIO PUIGVERT IUNA
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- FP2026/01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The investigators and the sponsor will preserve the confidentiality of all patients participating in the clinical trial, in accordance with GCP, and the patient's identity will be kept confidential throughout the trial. Complete affiliation data and written consent will be kept in the investigator's file.
The personal data of the participants will be treated in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on Data Protection (GDPR), and the corresponding Organic Law 3/2018, of 5 December, on the protection of personal data and the guarantee of digital rights. The data collected are only those data strictly necessary for the purposes of this research and will be used exclusively for this purpose.
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.